Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes
Orforglipron treatment was associated with beneficial changes in CV risk markers in participants with T2D and in participants with overweight/obesity without T2D. (Clinicaltrials.gov: NCT05048719, NCT05051579).
Authors
- Sean Wharton (ORCID: https://orcid.org/0000-0003-0111-1530)
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Hiya Banerjee (ORCID: https://orcid.org/0000-0003-1158-0330)
- Kieren J. Mather (ORCID: https://orcid.org/0000-0001-8696-7500)
- Valentina Pirro (ORCID: https://orcid.org/0000-0002-3924-6943)
- Kevin L. Duffin (ORCID: https://orcid.org/0000-0002-1656-8982)
- Manige Konige
- Christof Kazda (ORCID: https://orcid.org/0000-0002-2538-2573)
- Jonathan M. Wilson (ORCID: https://orcid.org/0000-0003-3681-1166)
- Yanzhu Lin
Institutions
- Eli Lilly (United States) (US)
- York University (CA)
- Velocity Clinical Research (United States) (US)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1186/s12933-025-02781-x
- Citations
- 10
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 12.95
Funders
- Eli Lilly and Company